Search

Your search keyword '"Brescia Morra, V"' showing total 59 results

Search Constraints

Start Over You searched for: Author "Brescia Morra, V" Remove constraint Author: "Brescia Morra, V" Topic humans Remove constraint Topic: humans
59 results on '"Brescia Morra, V"'

Search Results

1. Signs and symptoms of COVID-19 in patients with multiple sclerosis

2. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration

3. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis

4. The Italian multiple sclerosis register

5. Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis

6. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis

7. Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression

8. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

9. Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study

10. Natalizumab in the pediatric MS population: Results of the Italian registry

11. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

12. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

13. Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy

14. Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study

15. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

16. Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial

17. Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis - Results of the βPlus observational cohort study

18. Lipid composition of erythrocyte membranes in myotonic muscular dystrophy

19. Plasma lipoprotein concentration and erythrocyte membrane lipids in patients with Friedreich's ataxia

20. The effect of air pollution on COVID‐19 severity in a sample of patients with multiple sclerosis

21. Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis

22. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

23. Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis

24. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis

25. A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting

26. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study

27. Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis

28. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases

29. Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients

30. Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review

31. Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation

32. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

33. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients with Primary Progressive Multiple Sclerosis

34. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

35. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

36. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

37. Cognitive trajectories in multiple sclerosis: a long-term follow-up study

38. Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential

39. Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis

40. A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis

41. Assessing disability and relapses in multiple sclerosis on tele-neurology

42. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

43. Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19

44. Assessment of retinal vascular network in amnestic mild cognitive impairment by optical coherence tomography angiography

45. The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis

46. Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery

47. Glatiramer Acetate modulates ion channels expression and calcium homeostasis in B cell of patients with relapsing-remitting multiple sclerosis

48. Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin

49. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks

50. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML

Catalog

Books, media, physical & digital resources